Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells

References

• Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:1–14.
   Web of Science ®Google Scholar
• Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470–1476.
   PubMed Web of Science ®Google Scholar
• de Vrij J, Maas SLN, Kwappenberg KMC, et al. Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells. Int J Cancer. 2015;137:1630–1642.
   Web of Science ®Google Scholar
• Berenguer J, Lagerweij T, Zhao XW, et al. Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8. J Extracell Vesicles. 2018;7:1–21.
   Web of Science ®Google Scholar
• Izquierdo-Useros N, Lorizate M, Puertas MC et al. Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides. PLoS Biol. 2012;10:1–13.
   Web of Science ®Google Scholar
• Saunderson SC, Dunn AC, Crocker PR, et al. CD169 mediates the capture of exosomes in spleen and lymph node. Blood. 2014;123:208–216.
   PubMed Web of Science ®Google Scholar
• Zaia J. Mass spectrometry and glycomics. Supramol Struct Funct. 2010;9(14):89–102.
   Google Scholar
• Krishnamoorthy L, Bess JW, Preston AB, et al. HIV-1 and microvesicles from T cells share a common glycome, arguing for a common origin. Nat Chem Biol. 2009;5:244–250.
   PubMed Web of Science ®Google Scholar
• Batista BS, Eng WS, Pilobello KT, et al. Identification of a conserved glycan signature for microvesicles. J Proteome Res. 2011;10:4624–4633.
   PubMed Web of Science ®Google Scholar
• van der Vos KE, Abels ER, Zhang X et al. Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro Oncol. 2015;18:244.
   Web of Science ®Google Scholar
• Mallawaaratchy DM, Hallal S, Russell B, et al. Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease. J Neurooncol. 2017;131:233–244.
   PubMed Web of Science ®Google Scholar
• Van Der Vos KE, Abels ER, Zhang X, et al. Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro Oncol. 2016;18:58–69.
   PubMed Web of Science ®Google Scholar
• Wei Z, Batagov AO, Schinelli S, et al. Coding and noncoding landscape of extracellular RNA released by human glioma stem cells. Nat Commun. 2017;8.
   Web of Science ®Google Scholar
• Figueroa JM, Skog J, Akers J, et al. Detection of wild-Type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro Oncol. 2017;19:1494–1502.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, Van Den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996.
   PubMed Web of Science ®Google Scholar
• Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337–341.
   Web of Science ®Google Scholar
• Baratta MG. Glioblastoma is ‘hot’ for personalized vaccines. Nat Rev Cancer. 2019;245:41568.
   Google Scholar
• Keskin DB, Anandappa AJ, Sun J et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2018. DOI:10.1038/s41586-018-0792-9.
   Web of Science ®Google Scholar
• Ampie L, Woolf EC, Dardis C. Immunotherapeutic advancements for glioblastoma. Front Oncol. 2015;5:1–8.
   Web of Science ®Google Scholar
• Lim M, Xia Y, Bettegowda C, et al. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15:422–442.
   PubMed Web of Science ®Google Scholar
• Weller M, Roth P, Preusser M, et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol. 2017;13:363–374.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25:477–486.
   PubMed Web of Science ®Google Scholar
• Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma Letters. Nat Med. 2019;25:470–476.
   PubMed Web of Science ®Google Scholar
• Zhao J, Chen AX, Gartrell RD, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25:462–469.
   PubMed Web of Science ®Google Scholar
• Liau LM, Ashkan K, Tran DD et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018;16:1.
   PubMed Web of Science ®Google Scholar
• Platten M, Bunse L, Wick W, et al. Concepts in glioma immunotherapy. Cancer Immunol Immunother. 2016;65:1269–1275.
   Web of Science ®Google Scholar
• Weller M, Butowski N, Tran DD et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18:1373–1385.
   PubMed Web of Science ®Google Scholar
• Hilf N, Kuttruff-Coqui S, Frenzel K et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2018. DOI:10.1038/s41586-018-0810-y.
   PubMed Web of Science ®Google Scholar
• Ridler C. Personalized vaccines use tumour fingerprint to target glioblastoma. Nat Rev Neurol. 2019;15:2019.
   Web of Science ®Google Scholar
• Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo. Immunobiology. 2006;211:599–608.
   PubMed Web of Science ®Google Scholar
• Caminschi I, Maraskovsky E, Heath WR. Targeting dendritic cells in vivo for cancer therapy. Front Immunol. 2012;3:1–13.
   Web of Science ®Google Scholar
• Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106:255–258.
   PubMed Web of Science ®Google Scholar
• Jensen PE. Recent advances in antigen processing and presentation. Nat Immunol. 2007;8:1041–1048.
   PubMed Web of Science ®Google Scholar
• Neefjes J, Jongsma MLM, Paul P, et al. Towards a systems understanding of MHC class i and MHC class II antigen presentation. Nat Rev Immunol. 2011;11:823–836.
   PubMed Web of Science ®Google Scholar
• Syn NL, Wang L, Chow EKH, et al. Exosomes in cancer nanomedicine and immunotherapy: prospects and challenges. Trends Biotechnol. 2017;35:665–676.
   PubMed Web of Science ®Google Scholar
• Morelli AE, Larregina AT, Shufesky WJ et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood. 2004;104:3257–3266.
   PubMed Web of Science ®Google Scholar
• Wolfers J, Lozier A, Raposo G et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001;38:297–303.
   Web of Science ®Google Scholar
• Fehres CM, Garcia-Vallejo JJ, Unger WWJ, et al. Skin-resident antigen-presenting cells: instruction manual for vaccine development. Front Immunol. 2013;4:157.
   PubMed Web of Science ®Google Scholar
• Unger WWJ, Van Kooyk Y. ‘Dressed for success’ C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells. Curr Opin Immunol. 2011;23:131–137.
   PubMed Web of Science ®Google Scholar
• van Kooyk Y, Unger WWJ, Fehres CM, et al. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation. Mol Immunol. 2013;55:143–145.
   PubMed Web of Science ®Google Scholar
• Fehres CM, van Beelen AJ, Bruijns SCM, et al. In situ delivery of antigen to DC-SIGN + CD14 + dermal dendritic cells results in enhanced CD8 + T-cell responses. J Invest Dermatol. 2015;135:2228–2236.
   Web of Science ®Google Scholar
• Horrevorts SK, Duinkerken S, Bloem K, et al. Toll-like receptor 4 triggering promotes cytosolic routing of DC-SIGN-targeted antigens for presentation on MHC class I. Front Immunol. 2018;9:1–13.
   Web of Science ®Google Scholar
• Appelmelk BJ, van Die I, van Vliet SJ, et al. Cutting edge: carbohydrate profiling identifies new pathogens that interact with dendritic cell-specific ICAM-3-grabbing nonintegrin on dendritic cells. J Immunol. 2003;170:1635–1639.
   PubMed Web of Science ®Google Scholar
• Engering A, Geijtenbeek TBH, van Vliet SJ, et al. The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol. 2002;168:2118–2126.
   PubMed Web of Science ®Google Scholar
• Pontén J, MACINTYRE E. Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand. 1968;74:465–486.
   PubMedGoogle Scholar
• Wakimoto H, Kesari S, Farrell CJ et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009;69:3472–3481.
   PubMed Web of Science ®Google Scholar
• Bax M, García-Vallejo JJ, Jang-Lee J, et al. Dendritic cell maturation results in pronounced changes in glycan expression affecting recognition by siglecs and galectins. J Immunol. 2007;179:8216–8224.
   PubMed Web of Science ®Google Scholar
• Geijtenbeek TBH, Torensma R, van Vliet SJ, et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses efficient T cell activation (Hernandez-Caselles et al., 1993). Indeed, antibody engagement of ICAM-3 results in elevation of intracellular ca. Cell. 2000;100:575–585.
   PubMed Web of Science ®Google Scholar
• Thery C, Clayton A, Sebastian Amigorena GR. Isolation and characterization of exosomes from cell culture supernatants. Curr Protoc Cell Biol. 2006;supplement:1–29.
   Google Scholar
• Böing AN, Van Der Pol E, Grootemaat AE et al. Single-step isolation of extracellular vesicles from plasma by size-exclusion chromatography. Int Meet ISEV Rotterdam. 2014;3:118.
   Google Scholar
• Shelke GV, Lässer C, Gho YS, et al. Importance of exosome depletion protocols to eliminate functional and RNA-containing extracellular vesicles from fetal bovine serum. J Extracell Vesicles. 2014;3:1–8.
   Google Scholar
• Raposo G, Nijman HW, Stoorvogel W, et al. Lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996;183:1161–1172.
   PubMed Web of Science ®Google Scholar
• Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci. 2010;107:6328–6333.
   PubMed Web of Science ®Google Scholar
• Baglio SR, van Eijndhoven MAJ, Koppers-Lalic D, et al. Sensing of latent EBV infection through exosomal transfer of 5′pppRNA. Proc Natl Acad Sci. 2016;113:E587–E596.
   PubMed Web of Science ®Google Scholar
• Kotecha N, Krutzik PO, Irish JM. Web-based analysis and publication of flow cytometry experiments. Curr Protoc Cytom. 2010;53:10.17.1–10.17.24.
   Google Scholar
• Garcia-Vallejo JJ, Bloem K, Knippels LMJ, et al. The consequences of multiple simultaneous C-type lectin-ligand interactions: DCIR alters the endo-lysosomal routing of DC-SIGN. Front Immunol. 2015;6:1–12.
   Web of Science ®Google Scholar
• Maas SLN, De VJ, Broekman MLD Quantification and size-profiling of extracellular vesicles using tunable resistive pulse sensing. 1–7 (2014). doi:10.3791/51623
   Google Scholar
• Lötvall J, Hill AF, Hochberg F, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the international society for extracellular vesicles. J Extracell Vesicles. 2014;3:26913.
   PubMedGoogle Scholar
• Roy S, Lin H-Y, Chou C-Y, et al. Navigating the landscape of tumor extracellular vesicle heterogeneity. Int J Mol Sci. 2019;20:1–22.
   Web of Science ®Google Scholar
• Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7:255–266.
   PubMed Web of Science ®Google Scholar
• Lübbers J, Rodríguez E, Kooyk YV. Modulation of immune tolerance via siglec-sialic acid interactions. Front Immunol. 2018;9:1–13.
   Web of Science ®Google Scholar
• Zhang JQ, Nicoll G, Jones C, et al. Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes.. J Biol Chem. 2000;275:22121–22126.
   PubMed Web of Science ®Google Scholar
• Stanczak MA, Siddiqui SS, Trefny MP, et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest. 2018;128:4912–4923.
   PubMed Web of Science ®Google Scholar
• van Liempt E, Bank CMC, Mehta P, et al. Specificity of DC-SIGN for mannose- and fucose-containing glycans. FEBS Lett. 2006;580:6123–6131.
   Web of Science ®Google Scholar
• Boks MA, Ambrosini M, Bruijns SC, et al. MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses. J Control Release. 2015;216:37–46.
   Web of Science ®Google Scholar
• van Kooyk Y, Rabinovich G. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol. 2008;9:593–601.
   PubMed Web of Science ®Google Scholar
• Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - An ISEV position paper. J Extracell Vesicles. 2015;4.
   Web of Science ®Google Scholar
• Escrevente C, Grammel N, Kandzia S, et al. Sialoglycoproteins and N-glycans from secreted exosomes of ovarian carcinoma cells. PLoS One. 2013;8:e78631.
   PubMed Web of Science ®Google Scholar
• Barres C, Blanc L, Bette-Bobillo P et al. Galectin-5 is bound onto the surface of rat reticulocyte exosomes and modulates vesicle uptake by macrophages. Blood. 2010;115:696–706.
   PubMed Web of Science ®Google Scholar
• Christianson HC, Svensson KJ, van Kuppevelt TH, et al. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proc Natl Acad Sci. 2013;110:17380–17385.
   PubMed Web of Science ®Google Scholar
• Atai NA, Balaj L, van Veen H, et al. Heparin blocks transfer of extracellular vesicles between donor and recipient cells. J Neurooncol. 2013;115:343–351.
   Web of Science ®Google Scholar
• Hao S, Bai O, Li F et al. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology. 2006;120:90–102.
   Web of Science ®Google Scholar
• Sola RJ, Griebenow K. Glycosylation of therapeutic proteins an effective strategy to optimize efficacy. BioDrugs. 2010;24:9–21.
   PubMed Web of Science ®Google Scholar
• Gomes J, Gomes-Alves P, Carvalho S, et al. Extracellular vesicles from ovarian carcinoma cells display specific glycosignatures. Biomolecules. 2015;5:1741–1761.
   PubMed Web of Science ®Google Scholar
• García-vallejo JJ, Unger WWJ, Kalay H, et al. Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines. 1–3 (2013).
   Google Scholar
• Liu H, Chen L, Liu J, et al. Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma. Cancer Lett. 2017;411:182–190.
   PubMed Web of Science ®Google Scholar
• Andre F, Schartz NE, Movassagh M et al. Mechanisms of disease Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002;360:295–305.
   PubMed Web of Science ®Google Scholar
• Altevogt P, Bretz NP, Ridinger J, et al. Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. Semin Cancer Biol. 2014;28:51–57.
   Web of Science ®Google Scholar
• Peinado H, Alečković M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18:883–891.
   PubMed Web of Science ®Google Scholar
• Adams M, Navabi H, Croston D et al. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine. 2005;23:2374–2378.
   PubMed Web of Science ®Google Scholar
• Dai S, Wei D, Wu Z, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther. 2008;16:782–790.
   PubMed Web of Science ®Google Scholar
• Marleau AM, Chen CS, Joyce JA, et al. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med. 2012;10:1–12.
   Web of Science ®Google Scholar
• Brock CS, Newlands ES, Wedge SR et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58:4363–4367.
   PubMed Web of Science ®Google Scholar